Comparative Pharmacology
Head-to-head clinical analysis: KEFUROX versus ZINACEF IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KEFUROX versus ZINACEF IN PLASTIC CONTAINER.
KEFUROX vs ZINACEF IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting the final transpeptidation step of peptidoglycan synthesis, leading to cell lysis.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby blocking transpeptidation and leading to cell lysis and death.
750 mg to 1.5 g intramuscularly or intravenously every 8 hours; for severe infections, 1.5 g intravenously every 6 to 8 hours.
750 mg intravenously or intramuscularly every 8 hours; for severe infections, 1.5 g intravenously every 8 hours.
None Documented
None Documented
1.2-1.6 hours in adults with normal renal function (Clcr >80 mL/min); prolonged to 10-20 hours in end-stage renal disease (Clcr <10 mL/min).
Terminal elimination half-life is approximately 1.5 hours in adults with normal renal function; prolonged to 3-4 hours in neonates and up to 20-30 hours in end-stage renal disease.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Approximately 80-90% of the dose is excreted unchanged in the urine via glomerular filtration and tubular secretion; the remainder is eliminated via bile and feces.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic